Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications

NCT04322188 is registered in ClinicalTrials.gov with A.O. Ospedale Papa Giovanni XXIII as lead sponsor.

NCT NCT04322188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04322188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications
Lead sponsor
A.O. Ospedale Papa Giovanni XXIII
Phase
Observational
Overall status
Completed
Start date
March 19, 2020
Completion date
May 8, 2020
Enrollment
220 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe acute respiratory syndrome (ards) secondary to sars-cov-2 infection